Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Net Income (2020 - 2025)

Historic Net Income for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to -$12.7 million.

  • Tarsus Pharmaceuticals' Net Income rose 4599.99% to -$12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.0 million, marking a year-over-year increase of 3899.41%. This contributed to the annual value of -$115.6 million for FY2024, which is 1496.69% up from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Net Income is -$12.7 million, which was up 4599.99% from -$20.2 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year Net Income high stood at $10.4 million for Q1 2021, and its period low was -$42.5 million during Q4 2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' median Net Income value was -$22.5 million (recorded in 2022), while the average stood at -$20.1 million.
  • Its Net Income has fluctuated over the past 5 years, first surged by 63193.66% in 2021, then plummeted by 47411.81% in 2023.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Net Income stood at -$14.5 million in 2021, then increased by 5.96% to -$13.6 million in 2022, then plummeted by 211.62% to -$42.5 million in 2023, then skyrocketed by 45.63% to -$23.1 million in 2024, then skyrocketed by 45.06% to -$12.7 million in 2025.
  • Its Net Income was -$12.7 million in Q3 2025, compared to -$20.2 million in Q2 2025 and -$25.0 million in Q1 2025.